Login / Signup

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.

Junhua LyuYuxuan LiuLihu GongMingyi ChenYazan F MadanatYuannyu ZhangFeng CaiZhimin GuHui CaoPranita KaphleYoon Jung KimFatma N KalkanHelen StephensKathryn E DickersonMin NiWeina ChenPrapti A PatelAlice S MimsUma BorateAmy BurdSheng F CaiCheng Cameron YinMingjian James YouStephen S ChungRobert H CollinsRalph J DeBerardinisXin LiuJian Xu
Published in: Cancer discovery (2022)
Mutations in IDH genes occur frequently in acute myeloid leukemia (AML) and other human cancers to generate the oncometabolite R-2HG. Allosteric inhibition of mutant IDH suppresses R-2HG production in a subset of AML patients; however, acquired resistance emerges as a new challenge and the underlying mechanisms remain incompletely understood. Here we establish isogenic leukemia cells containing common IDH oncogenic mutations by CRISPR base editing. By mutational scanning of IDH single-amino acid variants in base-edited cells, we describe a repertoire of IDH second-site mutations responsible for therapy resistance through disabling uncompetitive enzyme inhibition. Recurrent mutations at NADPH binding sites within IDH heterodimers act in cis or trans to prevent the formation of stable enzyme-inhibitor complexes, restore R-2HG production in the presence of inhibitors, and drive therapy resistance in IDH-mutant AML cells and patients. We therefore uncover a new class of pathogenic mutations and mechanisms for acquired resistance to targeted cancer therapies.
Keyphrases